Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for the Treatment of Acute Intermediate-Risk Pulmonary Embolism

Next Previous
Trial Profile

Safety and Efficacy of Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for the Treatment of Acute Intermediate-Risk Pulmonary Embolism

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Low molecular weight heparins
  • Indications Pulmonary embolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PEITHO-2

Most Recent Events

  • 08 Nov 2020 This trial has been completed in Netherlands, according to European Clinical Trials Database record.
  • 28 Apr 2020 This trial has been completed in Austria according to European Clinical Trials Database record.
  • 23 Mar 2020 This trial has been completed in Belgium according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top